The IRMA Community
Newsletters
Research IRM
Click a keyword to search titles using our InfoSci-OnDemand powered search:
|
Quality by Design in Pharmaceutical Formulation
Abstract
Quality by design (QbD) is a systematic, scientific, risk-based approach to product development and manufacturing process to consistently deliver the quality product. In this chapter, application, benefits, opportunities, regulatory requirements involved in quality by design of pharmaceutical products are discussed. In quality by design approach, during development, the developer defines quality target product profile (QTPP) and identifies critical quality attributes (CQA). Critical process parameters (CPP) of unit operations which impacts critical quality attributes need to be identified to understand the impact of critical material attributes (CMA) on quality attributes of the drug product. Quality by design approach is defined in ICH guidelines Q8 – Pharmaceutical Development, Q9 – Quality Risk Management, Q10 – Pharmaceutical Quality System. This chapter describes the implementation of new concepts in quality by design like design of experiments to achieve design space, control strategy to consistently manufacture quality product throughout the product lifecycle.
Related Content
|
Sharon L. Burton.
© 2024.
25 pages.
|
|
Laura Ann Jones, Ian McAndrew.
© 2024.
24 pages.
|
|
Olayinka Creighton-Randall.
© 2024.
14 pages.
|
|
Stacey L. Morin.
© 2024.
11 pages.
|
|
N. Nagashri, L. Archana, Ramya Raghavan.
© 2024.
22 pages.
|
|
Esther Gani, Foluso Ayeni, Victor Mbarika, Abdullahi I. Musa, Oneurine Ngwa.
© 2024.
25 pages.
|
|
Sia Gholami, Marwan Omar.
© 2024.
18 pages.
|
|
|